Number (%) of patients in the trial who were on different antihypertensive treatments according to follow-up SBP, DBP, MAP, and pulse pressure above or below the median
| Parameter | SBP | DBP | MAP | Pulse Pressure | ||||
|---|---|---|---|---|---|---|---|---|
| Below | Above | Below | Above | Below | Above | Below | Above | |
| ACEi yes | 329 (55.6) | 263 (44.7)a | 325 (55.1) | 267 (45.3)a | 341 (57.7) | 251 (42.6)a | 308 (52.4) | 284 (48.0) |
| ndCCB yes | 298 (50.3) | 292 (49.7) | 307 (52.0) | 283 (48.0) | 307 (52.0) | 283 (48.0) | 292 (49.7) | 298 (50.3) |
| Veratran | 161 (27.2) | 132 (22.5) | 170 (28.8) | 123 (20.9)b | 174 (29.4) | 119 (20.2)a | 147 (25.0) | 146 (24.7) |
| Trandolapril | 168 (28.4) | 131 (22.3)c | 155 (26.3) | 144 (24.4) | 167 (28.3) | 132 (22.4)c | 161 (27.4) | 138 (23.3) |
| Verapamil | 137 (23.1) | 160 (27.2) | 137 (23.2) | 160 (27.1) | 133 (22.5) | 164 (27.8)c | 145 (24.7) | 152 (25.7) |
| Placebo | 126 (21.3) | 165 (28.1)b | 128 (21.7) | 163 (27.6)c | 117 (19.8) | 174 (29.5)a | 135 (23.0) | 156 (26.4) |
| Diuretic | 87 (14.7) | 142 (24.2)a | 100 (17.0) | 129 (21.9)c | 84 (14.2) | 145 (24.6)a | 99 (16.8) | 130 (22.0)c |
| β blocker | 42 (7.1) | 61 (10.4)c | 44 ( 7.5) | 59 (10.0) | 45 (7.6) | 58 (9.9) | 43 ( 7.3) | 60 (10.1) |
| dCCB | 84 (14.2) | 243 (41.3)a | 121 (20.5) | 206 (34.9)a | 79 (13.4) | 248 (42.1)a | 112 (19.1) | 215 (36.3)a |
| Sympatholytic agent | 179 (30.2) | 378 (64.3)a | 202 (34.2) | 355 (60.2)a | 174 (29.4) | 383 (65.0)a | 211 (35.9) | 346 (58.5)a |